Is a complete CLRB research report available?

No complete published report is available for Cellectar Biosciences, Inc. (CLRB) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Cellectar Biosciences, Inc. (CLRB)

NASDAQ: CLRB · USD

$2.53

+0.05 (+2.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first CLRB analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	20.2M
Net income (ttm)	-20.8M
EPS (ttm)	-$6.35
Shares out	8M
Volume	30,267
Beta	0.54
Price target	$11.5	+354.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -20.8M
EPS (ttm): -$6.35
Market cap: 20.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All CLRB indicators

Market & fundamental data

Available fields

190

Groups with data

Currency

USD

Showing 190 of 190 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001279704
Company name	Cellectar Biosciences, Inc.
Country	United States
Country code	US
Cusip	15117F880
Employees	11
Employees Change	-9%
Employees Change Percent	-45
Enterprise value	$13.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US15117F8804
Last refreshed	2026-07-31
Market cap	$20.2M
Market cap category	Nano-Cap
Price	$2.53
Price currency	USD
Sector	Healthcare
Sector PE	45.56
Sector PE Fwd	24.38
Sic	2834
Symbol	CLRB
Website	https://www.cellectar.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-103.07%
FCF yield	-91.94%
P/B ratio	3.81x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-20.8M
Net Income Growth Quarters	1%
Net Income Growth Years	1%
Profit Per Employee	$-1.9M
ROA	-103
Roa5y	-96.15
ROCE	-358.2
ROE	-290.4
ROIC	-171

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-55.47%
Cagr15y	-57.35%
Cagr1y	-46.31%
Cagr3y	-64.59%
Cagr5y	-62.46%
EPS Growth Quarters	1
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$11.1M
Cash	$8.3M
Current Assets	$9.3M
Current Liabilities	$4.9M
Debt	$1.5M
Debt Equity	$0.32
Equity	$4.7M
Liabilities	$6.4M
Long Term Assets	$1.9M
Long Term Liabilities	$1.5M
Net Cash	$6.8M
Net Cash By Market Cap	$33.72
Net Cash Growth	-49.23%
Net Debt Equity	$-1.45
Tangible Book Value	$2.8M
Tangible Book Value Per Share	$0.66
WACC	6.74

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.9
Net Working Capital	$-4M
Quick ratio	1.71
Working Capital	$4.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-141.46%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.97%
1Y total return	-46.28%
200-day SMA	3.09
3Y total return	-95.56%
50-day SMA	2.66
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.25%
All Time High	1,799,964
All Time High Change	-100%
All Time High Date	2011-04-11
All Time Low	2.2
All Time Low Change	15%
All Time Low Date	2026-06-12
ATR	0.18
Beta	0.54
Beta1y	2
Beta2y	1.35
Ch YTD	-14.24
High	2.61
High52	6.52
High52 Date	2025-10-06
High52ch	-61.2%
Low	2.48
Low52	2.2
Low52 Date	2026-06-16
Low52ch	15%
Ma50ch	-4.96%
Premarket Change Percent	0
Premarket Price	$2.48
Price vs 200-day SMA	-18.18%
RSI	47.04
RSI Monthly	26.77
RSI Weekly	41.36
Sharpe ratio	-0.41x
Sortino ratio	-0.53
Total Return	-141.46%
Tr YTD	-14.24
Tr15y	-100%
Tr1m	-2.69%
Tr1w	2.43%
Tr3m	-1.15%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	1
Analyst Price Target Top	$10
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.48
Operating Income	$-22.4M
Price target	$11.5
Price Target Change	$355
Price Target Change Top	$295

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	7,818,479%
Float Percent	97.83%
Shares Insiders	2.17%
Shares Institutions	17.26%
Shares Out	7,991,812
Shares Qo Q	3.2%
Shares Yo Y	141.46%
Short Float	2.55%
Short Ratio	1.39
Short Shares	2.5

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-20.7M
Adjusted OCF	-20,733,184
Average Volume	79,667.3x
Bv Per Share	0.66
CAPEX	$-9,258
Ch10y	-99.97
Ch15y	-100
Ch1m	-2.69
Ch1w	2.43
Ch1y	-46.28
Ch3m	-1.17
Ch3y	-95.56
Ch5y	-99.25
Ch6m	-21.91
Change	2.02%
Change From Open	-2.95
Close	2.48
Days Gap	5.12
Depreciation Amortization	210,701
Dollar Volume	76,575.5
Earnings Date	2026-08-13
Earnings Time	bmo
EBIT	$-22.4M
EBITDA	$-22.3M
EPS	$-6.35
F Score	1
FCF	$-18.6M
FCF EV Yield	-138.72x
FCF Per Share	$-2.33
Financing CF	13,031,523
Fiscal Year End	December
Founded	2,002
Investing CF	-9,258
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-14
Last Report Date	2026-03-31
Last Split Date	2025-06-24
Last Split Type	Reverse
Last10k Filing Date	2026-03-04
Ma150	2.94
Ma150ch	-14%
Ma20	2.6
Ma20ch	-2.5%
Net CF	-5,558,083
Next Earnings Date	2026-08-13
Open	2.61
Optionable	No
Position In Range	41.67
Post Close	2.53
Postmarket Change Percent	4.35
Postmarket Price	$2.64
Ppne	1,822,853
Pre Close	2.48
Price Date	2026-07-30
Ptbv Ratio	7.18
Relative Volume	0.38x
Share Based Comp	2,152,836
Tr6m	-21.91%
Us State	New Jersey
Volume	30,267

Cellectar Biosciences, Inc. (CLRB)

Coverage state: Market snapshot only — no published research

Generate the first CLRB analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · CLRB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CLRB indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on CLRB

Frequently asked questions